We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceutical launched its generic version of Mylan’s EpiPen Jr. (epinephrine) auto-injector 0.15mg at a wholesale cost of $300 per two-pack, the drugmaker announced Tuesday. Read More
The commission believes that a lack of competition between the two rival firms could harm competition in a market that’s long been prone to price-fixing. Read More
An antitrust lawsuit filed in a federal court in New York claims AstraZenica struck a deal with generic drugmakers to hold off on launching versions of its anti-psychotic drug Seroquel XR. Read More
Allergan has agreed to pay $2.74 million to three labor union health funds in a bid to bring antitrust litigation against the drugmaker to a close. The payments, revealed in documents filed in the U.S. District Court for Massachusetts, resolves claims from certain plaintiffs that alleged anticompetitive behavior related to the ulcerative colitis drug Asacol (mesalamine). Read More
Teva used four pay-for-delay agreements to illegally control sales of the drug between 2006 and 2012 and drove up the cost of the drug, the state’s attorney general said. Read More
Israeli drug titan Teva Pharmaceuticals and two other drugmakers have agreed to settlements in California in order to shake allegations of anticompetitive pay-for-delay deals. Read More
In a big week for Pfizer, the world’s second largest drugmaker earned the FDA’s approval for a biosimilar cancer treatment and signed up the agency’s former Commissioner Scott Gottlieb for its board. Read More